Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.39 |
| ▸ | CBFB | Q13951 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075633 | 0.92 | DHODH (0.45) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075635 | 0.92 | PLA2G2A (0.44) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075644 | 0.90 | PLA2G2A (0.43) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075631 | 0.89 | ESR1 (0.43) | ESRRBESR1ESRRAESR2MAPT | |
| SCHEMBL26075632 | 0.89 | MAPT (0.48) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075648 | 0.89 | KDM4E (0.44) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075636 | 0.89 | KDM4E (0.44) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075645 | 0.89 | KDM4E (0.44) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075649 | 0.88 | ESRRB (0.39) | ESRRBESR1ESRRAESR2PLA2G2A | |
| SCHEMBL26075641 | 0.84 | ESR1 (0.41) | ESRRBESR1ESRRAESR2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | ESRRB 4671/4885ESR1 4427/4885ESRRA 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.